Medpace Holdings Inc

Medpace Holdings Inc. is a contract research organization (CRO) that provides clinical development services for the pharmaceutical and biotechnology industries. A core part of this business involves conducting animal testing on behalf of client companies to support regulatory submissions for new drugs and medical devices. As a CRO, Medpace designs, manages, and reports on these preclinical and clinical trials, which routinely include animal studies as a required step in the drug development process. The company’s operations are fundamentally built on the commercial exploitation of animals in research.

While specific client studies and animal usage numbers are proprietary, the company’s regulatory guidance documents and standard operating procedures explicitly cover the management of animal testing protocols. This places Medpace within the research supply chain that depends on animal experimentation. The evidence gathered, while not detailing specific violations, confirms the company’s role in an industry where animal testing is a standard, large-scale practice. Without a publicly available animal welfare policy committing to the replacement of animal models where scientifically feasible, the company’s business model remains aligned with the ongoing commercial use of animals in research.